Strategies to Improve the Clinical Performance of Chimeric Antigen Receptor-Modified T Cells for Cancer

Publisher： Bentham Science Publishers

E-ISSN： 1875-5631|13|1|65-70

ISSN： 1566-5232

Source： Current Gene Therapy, Vol.13, Iss.1, 2013-02, pp. : 65-70

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Anti-EGFRvIII Chimeric Antigen Receptor-Modified T Cells for Adoptive Cell Therapy of Glioblastoma

By  

Current Pharmaceutical Design, Vol. 23, Iss. 14, 2017-05 ,pp. : 2113-2116

Bentham Science Publishers

Access to resources Recommend Favorite

Life or Death of T Cells with Antigen-Specific Receptors - Using T Cells for Cancer Adoptive Immunotherapy / Gene Therapy

By  

Current Gene Therapy, Vol. 1, Iss. 3, 2001-09 ,pp. : 253-255

Bentham Science Publishers

Access to resources Recommend Favorite

Building Better Chimeric Antigen Receptors for Adoptive T Cell Therapy

By  

Current Gene Therapy, Vol. 10, Iss. 2, 2010-04 ,pp. : 77-90

Bentham Science Publishers

Access to resources Recommend Favorite

Strategies to Overcome Drug Resistance of Receptor Tyrosine Kinaseaddicted Cancer Cells

By  

Current Medicinal Chemistry, Vol. 21, Iss. 14, 2014-05 ,pp. : 1607-1617

Bentham Science Publishers

Access to resources Recommend Favorite

Safety Strategies of Genetically Engineered T Cells in Cancer Immunotherapy

By  

Current Pharmaceutical Design, Vol. 24, Iss. 1, 2018-03 ,pp. : 78-83

Bentham Science Publishers

Access to resources Recommend Favorite